SCYNEXIS (SCYX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on SCYNEXIS (SCYX) is Moderate Underperform.

The composite score behind that read is -0.24, weighing +0.17 of bullish evidence against -0.35 bearish.

SCYNEXIS last closed at $5.03, -1.76% on the session.

Against the IVW growth benchmark the position is -2.68% over the forecast window.

The read is built from 11 underlying insights — 3 bullish and 8 bearish.

Agreement across those insights is 73%.

16 graded predictions for SCYX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks SCYNEXIS in the 27th percentile on return on equity, where 100 is best.

SCYNEXIS is classified under Health Care / Pharmaceuticals, with a market capitalisation of $50.94M.

StockMap tracks SCYNEXIS as the 96th largest of the 128 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 54 Moderate Underperform, 53 Neutral, 15 Strong Underperform and 6 Moderate Outperform.

On that composite SCYNEXIS ranks 65th of 128 in the group, against a group median of -0.24.